With a $250,000 award from the Pancreatic Cancer Action Network, researchers will seek to validate biomarkers able to detect pancreas cancer months or years before patients experience overt symptoms of the disease. Pancreatic ductal adenocarcinoma is the deadliest of the major cancer types, with a five-year survival rate of less than 10 percent. Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Principal investigator Brett Sheppard, … Read More
Posts Tagged ‘biomarker’
Scrutinizing the immune cells infiltrating a tumor may reveal the cancer’s vulnerability or resistance to immune-based therapies.
Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments. Less than 25 percent of newly diagnosed patients survive beyond five years with a standard of care based on 40-year-old chemotherapy agents. The research initiative, Beat AML, is supplying a stock of drug candidates and treatment ideas, a dozen of which were presented on Dec. 5-8 at … Read More
Researchers have identified many of the altered genes and cell signaling pathways that drive papillary renal cell carcinoma, a poorly understood form of cancer that accounts for about 15 percent of kidney tumors. The findings, published today in the New England Journal of Medicine, are likely to affect clinical recommendations, and should help guide the development of more precisely targeted therapies. No effective treatment exists for advanced papillary renal cell carcinoma.
Less than one in ten cases of pancreatic cancer in the U.S. are diagnosed at the local stage. And the relative survival rate — around 6 percent at five years — is by far the worst among major cancers. The OHSU Knight Cancer Institute and the Swedish biotech firm Immunovia AG recently announced a collaboration to develop blood tests that could enable earlier diagnosis of pancreatic cancer.